Navigation Links
Controversy Spikes Over Anti-diabetes Drug Avandia

Controversy over diabetes drug Avandia heated up Wednesday as experts pointed to studies linking it to greater heart attack risk, while a GSK study claimed rosiglitazone is safe.

The GlaxoSmithKline study published online Tuesday by the New England Journal of Medicine (NEJM) gave preliminary results of a four-year clinical study of 4,446 patients showing Avandia did not increase the rate of heart attacks or death.

Among the sub-group of patients who took Avandia, 29 died from heart attacks, against 35 who died from a control group taking two other drugs for adult-onset, type 2 diabetes, GSK said in the study.

In a study that analyzed 42 clinical trials published May 21 by NJEM, eminent cardiologist Steven Nissen of the Cleveland Clinic, in Ohio, said Avandia increased the risk of heart attacks by 43 percent.

The initial results of the GSK-funded research, the Record Study Group, which challenges Nissan's conclusions, failed to convince several well known US medical experts, said an NEJM editorial.

"The interim results of the Record trial do not provide assurance of the safety of treatment with rosiglitazone (Avandia).

If anything, it shows the opposite," said Massachusetts General Hospital diabetes expert David Nathan.

In a separate editorial in Tuesday's NEJM, Bruce Psaty of the University of Washington in Seattle and Curt Furberg of Wake Forest University, North Carolina, re-evaluated the heart risks in GSK's Record study using Nissen's methodology.

They found Avandia raised the risk of heart attack by 33 percent.

"In my mind, its not small," wrote Furberg, who said that extrapolating the results to the millions of diabetes patients taking Avandia meant thousands more people would have heart attacks.

The Committee on Oversight and Government Reform of the House of Representatives on Wednesday held a hearing on Avandia, focusing on the US Food and Drug Adm inistration's role in its approval in 1999.

The FDA has come under fire for approving Merck's anti-inflammation drug Vioxx, which was taken off the shelves in 2004 after it was linked to increased heart attacks and death.

"By examining Avandia ...

we can learn a lot about the drug approval and the post-market surveillance process," Democratic Representative Henry Waxman, of California, told the hearing.

"Avandia is a case study of the need for reform of the nation's drug safety laws," he added.

The House panel was keen on hearing from Rosemary Johann-Liang, from the FDA Office of Drug Safety, who in an NEJM interview said she had approved in March 2006 a recommendation from FDA inspectors to toughen a warning label on Avandia to stress its increased risk for heart attacks.

Johann-Liang said she was pressured to go back on her decision after FDA officials were contacted by GSK.

FDA Commissioner Andrew von Eschenbach, Nissan, and a GSK representative are expected to testify at the House hearing on Wednesday.


'"/>




Related medicine news :

1. Herbal Drug In Controversy
2. The Existing Controversy of Hormone Replacement Therapy
3. A Settlement Over Stem Cell Controversy Through Scientific Research
4. Controversy over spread of Mad Cow disease from India
5. French Fries In Cancer Controversy In China
6. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
7. Controversy: Malaria Vaccine - Future Possibility Or Just A Dream?
8. The Looming Controversy Surrounding Facial Transplant
9. Controversy over Healthy diet may lead to less red meat in diet
10. Controversy over Copeman Healthcare fee
11. The Publication Of Surgeon Specific Death Rates Raises Controversy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology: